IQ motif and Sec7 domain ArfGEF 2Genealiases: BRAG1 · IQ-ArfGEF · MRX1 · MRX18 · MRX78 · NEDXSB
Q-omics provides the consensus-scored IQSEC2 profile across patient tissues and cancer cell-line models. IQSEC2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in GBM. Among the 18 cancer types available for tumor–normal comparison, IQSEC2 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, IQSEC2 protein abundance shows 23,396 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight GBM, and COAD as cancer lineages where IQSEC2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IQSEC2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IQSEC2 survival associations across molecular data types. IQSEC2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IQSEC2 RNA expression–survival associations across cancer types. High IQSEC2 expression shows unfavorable associations in GBM, THCA and UVM, but favorable associations in ACC, CESC and MESO. The GBM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .010). Together, the overview and detailed table identify GBM as the clearest survival context for IQSEC2 RNA expression.
This table summarizes IQSEC2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in BRCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for IQSEC2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IQSEC2 shows lower tumor expression in COAD and READ and higher tumor expression in BRCA, KIRC, LIHC and CHOL. The COAD box plot shows higher IQSEC2 RNA expression in normal versus tumor tissue (log2 FC = −0.599, t-test p < 0.001).
This table shows molecular features associated with IQSEC2 in patient tissues and cancer cell lines. In patient samples, IQSEC2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, IQSEC2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and CNS.
